C4 and Roche Expand DAC Cancer Drug Collaboration
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
BASEL, Switzerland, March 30, 2026 Roche has announced the launch of its cobas® MPX-E assay, a next-generation 4-in-1 multiplex...
Basel, March 16, 2026 Roche announced the launch of a large-scale NVIDIA-powered AI factory, marking a major advancement in...
Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating...
Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...
BASEL, Switzerland, Oct. 6, 2025 — Roche announced that it has received CE-mark approval for the AI-based Kidney Klinrisk...
